CARY, N.C., December 6, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Azurity Pharmaceuticals as the sole specialty pharmacy provider for Danziten™ (nilotinib) indicated for adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and adult patients with chronic phase (CP) and accelerated phase (AP) resistant or intolerant to prior therapy that included imatinib.
Chronic myeloid leukemia is a rare but serious form of cancer that affects the bone marrow and blood. Characterized by the presence of the Philadelphia chromosome, Ph+ CML in the chronic phase can significantly impact the quality of life for those affected. The introduction of Danziten provides a new option for managing this condition. Danziten works by targeting the abnormal protein produced by the Philadelphia chromosome, effectively inhibiting its ability to promote cancer cell growth.
Danziten is a new formulation of nilotinib and the one and only nilotinib with no fasting restrictions. “We are thrilled to work with Azurity to be the sole specialty pharmacy to offer Danziten, which is another treatment advancement for patients battling Ph+ CML,” said Ela Lourido, vice president and general manager, Biologics by McKesson. “This launch underscores our commitment to advancing cancer care and improving the lives of those affected by this challenging condition.”
Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, the Biologics’ pharmacy team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For the full prescribing information, including boxed warning for Danziten, please click here. For more information about the treatment of patients with chronic myeloid leukemia, please click here.
All Rights Reserved. Danziten™ is a trademark of Azurity Pharmaceuticals, Inc. All trademarks referred to are the property of their respective owners. PP-DAN-US-0110